novo nordisk's semaglutide failed to slow alzheimer's disease progression Details of studies cast pall on GLP-1 as treatment GLP-1 Semaglutide Fails to Slow
Description
These medications were originally developed for the management of type 2 diabetes
Personalised dose escalation, nutritional guidance, hydration support and regular follow-up help minimise side effects while supporting safer, more sustainable outcomes
Your provider will review this with you before prescribing
We will let you know promptly if a breach occurs that may have compromised the privacy or security of your information
If you have a question about an order, your care team can help
